SELLAS Life Sciences (SLS) Free Cash Flow (2010 - 2026)
SELLAS Life Sciences (SLS) reported Free Cash Flow of -$8.8 million for Q1 2026, up 2.98% year-over-year from -$8.5 million in Q1 2025, and down 79.59% on a QoQ basis from -$4.9 million in Q4 2025.
SELLAS Life Sciences (SLS) has 17 years of Free Cash Flow data on file, last reported at -$8.8 million in Q1 2026.
- Quarterly Free Cash Flow rose 2.98% year-over-year to -$8.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.1 million (up 16.56% YoY) and the FY2025 annual result came in at -$28.4 million, up 19.78% from the prior year.
- Free Cash Flow eased to -$8.8 million in Q1 2026 per SLS's latest filing, from -$4.9 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$4.8 million in Q4 2023 and bottomed at -$12.1 million in Q1 2023.
- The 5-year median for Free Cash Flow is -$7.2 million (2024), against an average of -$7.5 million.
- The widest annual swing landed in 2023, when Free Cash Flow slumped 69.61%; it then soared 31.5% in 2025.
- Tracing SLS's Free Cash Flow over 5 years: stood at -$5.2 million in 2022, then rose by 6.35% to -$4.8 million in 2023, then slumped by 48.25% to -$7.2 million in 2024, then surged by 31.5% to -$4.9 million in 2025, then slumped by 79.59% to -$8.8 million in 2026.
- Per Business Quant, the three latest SLS Free Cash Flow figures stand at -$8.8 million (Q1 2026), -$4.9 million (Q4 2025), and -$7.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 48.67 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | -8.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.80 Mn |
| Mar 31, 2026 | -8.80 Mn |
| Dec 31, 2025 | -4.90 Mn |
| Dec 31, 2025 | -4.90 Mn |
| Sep 30, 2025 | -7.10 Mn |
| Sep 30, 2025 | -7.10 Mn |
| Jun 30, 2025 | -7.33 Mn |
| Jun 30, 2025 | -7.33 Mn |
| Mar 31, 2025 | -9.07 Mn |
| Mar 31, 2025 | -9.07 Mn |
| Dec 31, 2024 | -7.15 Mn |
| Dec 31, 2024 | -7.15 Mn |
| Sep 30, 2024 | -7.81 Mn |
| Sep 30, 2024 | -7.81 Mn |
| Jun 30, 2024 | -9.68 Mn |
| Jun 30, 2024 | -9.68 Mn |
| Mar 31, 2024 | -10.76 Mn |
| Mar 31, 2024 | -10.76 Mn |
| Dec 31, 2023 | -4.83 Mn |
| Dec 31, 2023 | -4.83 Mn |
| Sep 30, 2023 | -6.89 Mn |
| Sep 30, 2023 | -6.89 Mn |
| Jun 30, 2023 | -7.57 Mn |
| Jun 30, 2023 | -7.57 Mn |
| Mar 31, 2023 | -12.13 Mn |
| Mar 31, 2023 | -12.13 Mn |
| Dec 31, 2022 | -5.15 Mn |
| Dec 31, 2022 | -5.15 Mn |
| Sep 30, 2022 | -5.75 Mn |
| Sep 30, 2022 | -5.75 Mn |
| Jun 30, 2022 | -5.76 Mn |
| Jun 30, 2022 | -5.76 Mn |
| Mar 31, 2022 | -7.15 Mn |
| Mar 31, 2022 | -7.15 Mn |
| Dec 31, 2021 | -4.98 Mn |
| Dec 31, 2021 | -4.98 Mn |
| Sep 30, 2021 | -5.88 Mn |
| Sep 30, 2021 | -5.88 Mn |
| Jun 30, 2021 | -4.90 Mn |
| Jun 30, 2021 | -4.90 Mn |
| Mar 31, 2021 | -10.27 Mn |
| Mar 31, 2021 | -10.27 Mn |
| Dec 31, 2020 | 3.42 Mn |
| Dec 31, 2020 | 3.42 Mn |
| Sep 30, 2020 | -3.63 Mn |
| Sep 30, 2020 | -3.63 Mn |
| Jun 30, 2020 | -3.38 Mn |
| Jun 30, 2020 | -3.38 Mn |
| Mar 31, 2020 | -6.83 Mn |
| Mar 31, 2020 | -6.83 Mn |
| Dec 31, 2019 | -4.18 Mn |
| Dec 31, 2019 | -4.18 Mn |
| Sep 30, 2019 | -3.82 Mn |
| Sep 30, 2019 | -3.82 Mn |
| Jun 30, 2019 | -4.66 Mn |
| Jun 30, 2019 | -4.66 Mn |
| Mar 31, 2019 | -4.99 Mn |
| Mar 31, 2019 | -4.99 Mn |
| Dec 31, 2018 | -4.56 Mn |
| Dec 31, 2018 | -4.56 Mn |
| Sep 30, 2018 | -14.17 Mn |
| Sep 30, 2018 | -14.17 Mn |
| Jun 30, 2018 | -6.30 Mn |
| Jun 30, 2018 | -6.30 Mn |
| Mar 31, 2018 | -5.40 Mn |
| Mar 31, 2018 | -5.40 Mn |
| Dec 31, 2017 | -1.74 Mn |
| Dec 31, 2017 | -1.74 Mn |
| Sep 30, 2017 | -2.40 Mn |
| Sep 30, 2017 | -2.40 Mn |
| Jun 30, 2017 | -3.05 Mn |
| Jun 30, 2017 | -3.05 Mn |
| Mar 31, 2017 | -3.80 Mn |
| Mar 31, 2017 | -3.80 Mn |
| Dec 31, 2016 | 15.92 Mn |
| Dec 31, 2016 | 15.92 Mn |
| Sep 30, 2016 | -10.17 Mn |
| Sep 30, 2016 | -10.17 Mn |
| Jun 30, 2016 | -7.85 Mn |
| Jun 30, 2016 | -7.85 Mn |
| Mar 31, 2016 | -9.75 Mn |
| Mar 31, 2016 | -9.75 Mn |
| Dec 31, 2015 | -5.55 Mn |
| Dec 31, 2015 | -5.55 Mn |
| Sep 30, 2015 | -13.44 Mn |
| Sep 30, 2015 | -13.44 Mn |
| Jun 30, 2015 | -8.97 Mn |
| Jun 30, 2015 | -8.97 Mn |
| Mar 31, 2015 | -11.00 Mn |
| Mar 31, 2015 | -11.00 Mn |
| Dec 31, 2014 | -8.30 Mn |
| Dec 31, 2014 | -8.30 Mn |
| Sep 30, 2014 | -7.74 Mn |
| Sep 30, 2014 | -7.74 Mn |
| Jun 30, 2014 | -12.98 Mn |
| Jun 30, 2014 | -12.98 Mn |
| Mar 31, 2014 | -8.07 Mn |
| Mar 31, 2014 | -8.07 Mn |
| Dec 31, 2013 | -2.61 Mn |
| Dec 31, 2013 | -2.61 Mn |
| Sep 30, 2013 | -8.09 Mn |
| Sep 30, 2013 | -8.09 Mn |
| Jun 30, 2013 | -7.12 Mn |
| Jun 30, 2013 | -7.12 Mn |
| Mar 31, 2013 | -5.33 Mn |
| Mar 31, 2013 | -5.33 Mn |
| Dec 31, 2012 | -5.18 Mn |
| Dec 31, 2012 | -5.18 Mn |
| Sep 30, 2012 | -4.17 Mn |
| Sep 30, 2012 | -4.17 Mn |
| Jun 30, 2012 | -6.75 Mn |
| Jun 30, 2012 | -6.75 Mn |
| Mar 31, 2012 | -4.89 Mn |
| Mar 31, 2012 | -4.89 Mn |
| Dec 31, 2011 | -4.17 Mn |
| Dec 31, 2011 | -4.17 Mn |
| Sep 30, 2011 | -3.41 Mn |
| Sep 30, 2011 | -3.41 Mn |
| Jun 30, 2011 | -4.07 Mn |
| Jun 30, 2011 | -4.07 Mn |
| Mar 31, 2011 | -3.07 Mn |
| Mar 31, 2011 | -3.07 Mn |
| Dec 31, 2010 | -1.91 Mn |
| Dec 31, 2010 | -1.91 Mn |
| Sep 30, 2010 | -2.25 Mn |
| Sep 30, 2010 | -2.25 Mn |